AstraZeneca announces top-line results of OSKIRA-4 Phase IIb study of fostamatinib as a monotherapy for rheumatoid arthritis
13 December 2012 | By AstraZeneca
Top-line results of OSKIRA-4...
List view / Grid view
13 December 2012 | By AstraZeneca
Top-line results of OSKIRA-4...
13 December 2012 | By Abbott
Acute chest pain is one of the most common reasons people seek emergency care...
13 December 2012 | By Amgen
Amgen announced appointments to its Board of Directors...
12 December 2012 | By Bristol-Myers Squibb Company
Global license and two year collaboration for Recothrom®...
12 December 2012 | By Roche
Roche announced plans to invest over 240 million Swiss francs in its Penzberg biotechnology centre...
12 December 2012 | By Gilead Sciences
Gilead Sciences and YM BioSciences announced that the companies have signed a definitive agreement...
12 December 2012 | By Biogen Idec
Biogen Idec and Eisai Inc. announced a strategic alliance...
11 December 2012 | By University of Lincoln
The new School of Pharmacy has been officially established at the University of Lincoln. It will be located within the soon-to-be-built science and innovation park...
11 December 2012 | By AstraZeneca
AstraZeneca and Isis Pharmaceuticals, Inc. announced a strategic alliance...
11 December 2012 | By kdm communications limited
Tecan recently hosted the fifth annual Tecan Symposium in the picturesque surroundings of Boston, Massachusetts...
11 December 2012 | By Novartis
Novartis announced long-term follow-up data...
11 December 2012 | By Boehringer Ingelheim
Boehringer Ingelheim’s Metacam® has obtained EU wide marketing authorizations...
10 December 2012 | By Red Consultancy
Results from a completed phase II study...
10 December 2012 | By GlaxoSmithKline
Partnership aims to create sustainable and scalable model to be replicated across Africa...
10 December 2012 | By Boehringer Ingelheim
Results from a new post-hoc analysis...